Article
Biochemistry & Molecular Biology
Timea Magdolna Szabo, Elod Erno Nagy, Adam Kirchmaier, Erhard Heidenhoffer, Hunor-Laszlo Gabor-Kelemen, Marius Frasineanu, Judit Cseke, Marta German-Sallo, Attila Frigy, Jun Sun
Summary: Vitamin D plays an important role as a prognostic biomarker in heart failure, although its therapeutic implications are still debated. This study found a close correlation between 25(OH)D and LVEF, as well as a significant positive correlation between 25(OH)D, serum uric acid, and albumin levels in HF patients. Furthermore, 25(OH)D concentration independently affected LVEF, supporting the need for establishing proper vitamin D supplementation schemes and dietary interventions in HF.
Article
Cardiac & Cardiovascular Systems
Shaoping Wang, Bijan J. Borah, Shujuan Cheng, Shiying Li, Ze Zheng, Xiaoyan Gu, Ming Gong, Yi Lyu, Jinghua Liu
Summary: The study found that diabetic patients had greater EF improvement after revascularization, and had higher risk of overall mortality. However, in the EF improved group, the risk was similar between diabetic and non-diabetic patients. Therefore, further research is needed to determine the indication for revascularization in patients with coronary artery disease.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Hayley E. Billingsley, Marco Giuseppe Del Buono, Justin M. Canada, Youngdeok Kim, Juan Ignacio Damonte, Cory R. Trankle, Geza Halasz, Virginia Mihalick, Alessandra Vecchie, Roshanak R. Markley, Dinesh Kadariya, Edoardo Bressi, Horacio Medina de Chazal, Juan Guido Chiabrando, James Mbualungu, Jeremy Turlington, Ross Arena, Benjamin W. Van Tassell, Antonio Abbate, Salvatore Carbone
Summary: Sarcopenia has a significant negative impact on cardiorespiratory fitness, even in obese patients with heart failure.
CIRCULATION-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Li Shen, Pardeep Singh Jhund, Kieran Francis Docherty, Muthiah Vaduganathan, Mark Colquhoun Petrie, Akshay Suvas Desai, Lars Kober, Morten Schou, Milton Packer, Scott David Solomon, Xingwei Zhang, John Joseph Valentine McMurray
Summary: Previous guidelines for treating heart failure with reduced ejection fraction recommended initiating therapy in a chronological order based on trial history. However, this study suggests that accelerating treatment titration and optimizing treatment ordering may improve patient outcomes.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Patrick M. Pilz, Jennifer E. Ward, Wei-Ting Chang, Attila Kiss, Edward Bateh, Alokkumar Jha, Sudeshna Fisch, Bruno K. Podesser, Ronglih Liao
Summary: This article outlines the strengths, limitations, and outcomes of small and large animal models of heart failure with reduced ejection fraction currently used in basic and translational research. Animal models play a critical role in understanding the molecular mechanisms of heart failure, although no model completely recapitulates the full human disease.
CIRCULATION RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Stefano Coiro, Nicolas Girerd, John J. V. McMurray, Bertram Pitt, Karl Swedberg, Dirk J. van Veldhuisen, Zohra Lamiral, Patrick Rossignol, Faiez Zannad
Summary: Loop diuretic usage, especially at doses > 40 mg, identified patients at higher risk than history of HF hospitalization and/or high BNP blood concentrations.
CLINICAL RESEARCH IN CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Robert J. H. Miller, Majid Nabipoor, Erik Youngson, Gynter Kotrri, Nowell M. Fine, Jonathan G. Howlett, Ian D. Paterson, Justin Ezekowitz, Finlay A. McAlister
Summary: Among patients with HFmrEF, those with positive LVEF trajectory are less likely to experience adverse outcomes after adjusting for important confounders, including medical therapy. Categorizing HFmrEF patients based on LVEF trajectory provides meaningful clinical information and may assist clinicians with management decisions.
Article
Cardiac & Cardiovascular Systems
Yogesh N. Reddy, Barry A. Borlaug, Bernard J. Gersh
Summary: Atrial fibrillation is the most common arrhythmia in heart failure patients and can be both the cause and consequence of clinical heart failure. Some patients may benefit from maintaining sinus rhythm with catheter ablation. There is a close relationship between atrial fibrillation, left atrial myopathy, mitral regurgitation, and heart failure with preserved ejection fraction, with potential clinical benefits to catheter ablation therapy. Treatment of atrial fibrillation also requires consideration of the degree of atrial myopathy and chronicity of atrial fibrillation.
Review
Pharmacology & Pharmacy
Orly Vardeny, Hailee Houle
Summary: The mineralocorticoid receptor is involved in cardiac tissue inflammation, fibrosis, and dysfunction in heart failure. Mineralocorticoid receptor antagonists (MRA) are recommended in heart failure with reduced ejection fraction (HFrEF), but their use in heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) is less supported. Careful patient selection is crucial for optimizing the use of MRA in these conditions. This review discusses the rationale for MRA use, summarizes clinical trial evidence, and explores nonsteroidal MRA in HFmrEF/HFpEF.
Article
Cardiac & Cardiovascular Systems
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Naveed Sattar, Martina Brueckmann, Waheed Jamal, Daniel Cotton, Tomoko Iwata, Faiez Zannad
Summary: The study found that the SGLT2 inhibitor empagliflozin had beneficial effects on patients with heart failure, including reducing the risk of heart failure events, decreasing hospitalizations, and improving health status and functional class. However, the study does not support a dominant role of diuresis in mediating the physiological changes or clinical benefits of SGLT2 inhibitors in patients with reduced ejection fraction.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Kazushi Sakane, Yumiko Kanzaki, Kosuke Tsuda, Daichi Maeda, Koichi Sohmiya, Masaaki Hoshiga
Summary: This study found that different factors were associated with disproportionately low BNP levels in patients with different types of heart failure. High BMI, lower blood pressure, and history of cardiovascular surgery were related to disproportionately low BNP in the HFpEF group, while high BMI and smaller left ventricular end-diastolic volume index were associated with disproportionately low BNP in the HFrEF group.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Medicine, General & Internal
Shinji Kishimoto, Tatsuya Maruhashi, Masato Kajikawa, Takahiro Harada, Takayuki Yamaji, Yiming Han, Aya Mizobuchi, Yu Hashimoto, Kenichi Yoshimura, Yukiko Nakano, Kazuaki Chayama, Chikara Goto, Farina Mohamad Yusoff, Ayumu Nakashima, Yukihito Higashi
Summary: The study found that both endothelial function and vascular smooth muscle function are impaired in patients with HFmrEF, with low NID <7.0% predicting future deterioration of LVEF.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Senthil Selvaraj, Jessica Kim, Bilal A. Ansari, Lei Zhao, Mary Ellen Cvijic, Matthew Fronheiser, Jagan Mohan-Rao Vanjarapu, Anupam A. Kumar, Arpita Suri, Sowjanya Yenigalla, Vaibhav Satija, Armghan Haider Ans, Offdan Narvaez-Guerra, Karela Herrera-Enriquez, Mary Jo Obeid, Jonathan J. Lee, Qasim Jehangir, Dietmar A. Seiffert, Bruce D. Car, David A. Gordon, Julio A. Chirinos
Summary: This study found distinct abnormalities in body composition between HFpEF and HFrEF, with reduced axial SM, not fat, independently predicting mortality in HF patients. NT-proBNP levels were more closely related to axial SM mass than fat distribution or BMI. Lower NT-proBNP levels in HFpEF compared with HFrEF relate more closely to muscle mass than obesity.
JACC-CARDIOVASCULAR IMAGING
(2021)
Review
Medicine, General & Internal
Carlo Lavalle, Luca Di Lullo, Jean Pierre Jabbour, Marta Palombi, Sara Trivigno, Marco Valerio Mariani, Francesco Summaria, Paolo Severino, Roberto Badagliacca, Fabio Miraldi, Antonio Bellasi, Carmine Dario Vizza
Summary: Patients with heart failure (HFrEF) often experience worsening symptoms despite continued therapy. Worsening heart failure accounts for a significant proportion of hospital admissions and carries higher risks of death and hospitalization. New drugs are emerging to address the residual risk of hospitalization and cardiovascular deaths in patients with worsening heart failure.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Luca Monzo, Nicolas Girerd, Kevin Duarte, Joao Pedro Ferreira, John J. V. McMurray, Dirk J. van Veldhuisen, Karl Swedberg, Stuart J. Pocock, Bertram Pitt, Faiez Zannad
Summary: This study evaluated the time course of benefits of Eplerenone in patients with HFrEF. The results showed that Eplerenone significantly reduced the risk of cardiovascular death or first hospitalization shortly after treatment initiation. This emphasizes the importance of early initiation of Eplerenone as part of guideline-directed medical therapy.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Niklas Dyrby Johansen, Muthiah Vaduganathan, Deewa Zahir, Mona Fiuzat, Ersilia M. DeFilippis, James L. Januzzi, Javed Butler, Christopher M. O'Connor, William T. Abraham, Mitchell A. Psotka, John J. V. McMurray, Pooja Dewan, Brian L. Claggett, Scott D. Solomon, Daniel Modin, Jawad H. Butt, Jens Ulrik Staehr Jensen, Morten Schou, Christian Torp-Pedersen, Lars Kober, Gunnar H. Gislason, Tor Biering-Sorensen
Summary: This study validated the use of a composite medical therapy score in Danish heart failure patients and found that higher scores were associated with lower mortality.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Wasyla Ibrahim, Pooja Dewan, Akshay S. Desai, Lars Kober, Margaret F. Prescott, Martin P. Lefkowitz, Jean L. Rouleau, Scott D. Solomon, Michael R. Zile, Milton Packer, Pardeep S. Jhund, John J. V. McMurray
Summary: This study examined the relationship between ucGMP/BNP ratio and clinical outcomes, as well as the impact of Sacubitril/valsartan on ucGMP/BNP ratio and clinical outcomes. The study found that higher ucGMP/BNP ratio was associated with better outcomes, and Sacubitril/valsartan increased ucGMP/BNP ratio compared to enalapril, with consistent effects on clinical outcomes regardless of baseline ucGMP/BNP ratio.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jean-Claude Tardif, Jean Rouleau, Glenn M. Chertow, Ayman Al-Shurbaji, Vera Lisovskaja, Stephanie Gustavson, Yanli Zhao, Nadia Bouabdallaoui, Akshay S. Desai, Alexander Chernyavskiy, Maria Evsina, Bela Merkely, John J. V. McMurray, Marc A. Pfeffer
Summary: The PRIORITIZE-HF study, which aimed to evaluate the benefits and risks of using SZC to intensify RAAS inhibitor therapy in patients with heart failure and reduced ejection fraction (HFrEF), was prematurely terminated due to challenges related to the COVID-19 pandemic. The study did not demonstrate a statistically significant increase in the intensity of RAAS inhibitor therapies with SZC compared to placebo.
Article
Cardiac & Cardiovascular Systems
Nicolas Girerd, Daniel Levy, Kevin Duarte, Joao Pedro Ferreira, Christie Ballantyne, Timothy Collier, Anne Pizard, Jens Bjoerkman, Javed Butler, Andrew Clark, John G. Cleland, Christian Delles, Javier Diez, Arantxa Gonzalez, Mark Hazebroek, Jennifer Ho, Anne-Cecile Huby, Shih-Jen Hwang, Roberto Latini, Beatrice Mariottoni, Alexandre Mebazaa, Pierpaolo Pellicori, Naveed Sattar, Peter Sever, Jan A. Staessen, Job Verdonschot, Stephane Heymans, Patrick Rossignol, Faiez Zannad
Summary: This study identified protein biomarkers associated with new-onset heart failure in three independent cohorts. The inclusion of these biomarkers in addition to clinical risk factors improved the prediction of heart failure risk. The B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide were found to be particularly relevant in predicting heart failure.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Q. d'Herve, N. Girerd, E. Bozec, Z. Lamiral, V. Panisset, L. Frimat, O. Huttin, S. Girerd
Summary: This study aimed to assess changes in echocardiographic parameters following kidney transplantation (KT) and identify factors associated with these changes. The results showed an increase in left atrial volume index (LAVI) after KT, and factors such as age, cardiac valvular disease, lower post-KT hemoglobin levels, and post-KT hypertension were associated with an increase in LAVI.
CLINICAL RESEARCH IN CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Khawaja M. Talha, Javed Butler, Stephen J. Greene, Rahul Aggarwal, Stefan D. Anker, Brian L. Claggett, Kieran F. Docherty, Scott D. Solomon, John J. V. McMurray, James L. Januzzi, Muthiah Vaduganathan, Gregg C. Fonarow
Summary: This study evaluated the potential implications of optimal global implementation of SGLT-2 inhibitors in heart failure, and found that it could prevent or postpone approximately 7-8 million worsening heart failure events and cardiovascular deaths worldwide, which is of great significance.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Stephen J. H. Dobbin, Li Shen, Mark C. Petrie, Milton Packer, Scott D. Solomon, John J. V. McMurray, Ninian N. N. Lang, Pardeep S. Jhund
Summary: This study examined the association between cancer history and outcomes in heart failure patients. It was found that heart failure patients with a history of cancer had a higher risk of hospitalization and non-cardiovascular death, but the risks of cardiovascular and all-cause death were similar. In heart failure patients with preserved ejection fraction, the presence or absence of cancer history did not affect the outcomes. The incidence of new cancer diagnoses was similar in both heart failure groups.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Nicolas Girerd
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Kieran F. Docherty, Mikhail N. Kosiborod, Silvio E. Inzucchi, Lars Kober, Anna Maria Langkilde, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjoestrand, Scott Solomon, Pardeep S. Jhund, John J. V. Mcmurray
Summary: This study examined the effects of dapagliflozin on physical and social limitations in patients with heart failure and found that it improved their quality of life and physical activity.
JACC-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Lars Kober, Carolyn S. P. Lam, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Sanjiv J. Shah, Muthiah Vaduganathan, Pardeep S. Jhund, Scott D. Solomon, John J. V. McMurray
Summary: This study found that gout is common in patients with heart failure and sodium-glucose cotransporter 2 inhibitors can reduce uric acid levels. Gout was associated with worse clinical outcomes, but the efficacy of dapagliflozin was consistent in patients with and without gout. Dapagliflozin also reduced the initiation of new treatments for hyperuricemia and gout.
Article
Cardiac & Cardiovascular Systems
Mingming Yang, Toru Kondo, Jawad H. Butt, William T. Abraham, Inder S. Anand, Akshay S. Desai, Lars Kober, Milton Packer, Marc A. Pfeffer, Jean L. Rouleau, Marc S. Sabatine, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, John J. McMurray
Summary: Patients with heart failure who have a history of stroke are at a high risk of subsequent cardiovascular events, regardless of ejection fraction. This study investigated the prevalence of stroke history in patients with heart failure and found that they had more vascular comorbidity and worse heart failure compared to those without stroke history. Targeting underutilization of guideline-recommended treatments might improve outcomes in this high-risk population.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Ankeet S. Bhatt, Mikhail N. Kosiborod, Brian L. Claggett, Zi Michael Miao, Muthiah Vaduganathan, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, James C. Fang, Yaling Han, Josep Comin-Colet, Jaroslaw Drozdz, Orly Vardeny, Bela Merkely, Daniel Lindholm, Magnus Peterson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: This study aimed to evaluate the association between COVID-19 and clinical outcomes in patients with chronic heart failure. The study found that COVID-19 was common among the participants, with over 50% of cases leading to hospitalization or death. COVID-19 diagnosis was significantly associated with an increased risk of death in the 12 months following diagnosis. Additionally, dapagliflozin showed treatment benefits in reducing cardiovascular death/worsening heart failure events.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Geriatrics & Gerontology
Mariam Elmegaard Malik, Jawad Haider Butt, Jarl Emanuel Strange, Alexander Christian Falkentoft, Jesper Jensen, Charlotte Andersson, Deewa Zahir, Emil Fosbol, Mark C. Petrie, Naveed Sattar, John J. McMurray, Lars Kober, Morten Schou
Summary: This study examined the impact of frailty on the initiation of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease. It was found that frail patients had a significantly lower probability of initiating these two drug therapies, indicating the need for clear guidelines for their use in this population.
LANCET HEALTHY LONGEVITY
(2023)
Letter
Medicine, General & Internal
Nathalie Conrad, John J. McMurray
Letter
Medicine, General & Internal
Nathalie Conrad, John J. V. McMurray